Biotech Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Entropin, Inc.
ENT-103 receives positive review from panel of pain experts
May 14th, 2003
Entropin, Inc., (ETOP) announced that a panel of pain experts retained by Entropin reviewed its preclinical program and found that the preclinical data continues to support the development of ENT-103 as a potential analgesic/anesthetic, in particular for the treatment of post-incisional pain. The expert panel reviewed Entropin's preclinical research and concluded: ENT-103 is an active compound; ENT-103 is a locally acting analgesic/anesthetic; ENT-103 activity has been confirmed independently by two institutions, Harvard Medical School and the University of Arizona; Preclinical data support the continued development of...
Source: Biotech Week (2003-05-14)
|
